Compare BHRB & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHRB | ABSI |
|---|---|---|
| Founded | 1852 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.8M | 997.8M |
| IPO Year | 2023 | 2021 |
| Metric | BHRB | ABSI |
|---|---|---|
| Price | $72.79 | $9.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $71.80 | $6.96 |
| AVG Volume (30 Days) | 114.9K | ★ 2.9M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 173.76 | 10.64 |
| EPS | ★ 2.16 | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | $36.62 | $215.96 |
| Revenue Next Year | $10.06 | $319.10 |
| P/E Ratio | $33.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $57.42 | $2.24 |
| 52 Week High | $75.09 | $12.06 |
| Indicator | BHRB | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 58.54 |
| Support Level | $60.93 | $2.56 |
| Resistance Level | $74.06 | $12.06 |
| Average True Range (ATR) | 1.54 | 0.58 |
| MACD | -0.18 | 0.18 |
| Stochastic Oscillator | 55.03 | 89.25 |
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.